Document:

EX-10.51

 Exhibit 10.51 

BIOVENTUS INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY 
 Non-employee members of the board of directors (the
“Board”) of Bioventus Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation
Policy (this “Policy”). The cash and equity compensation described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an
employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This Policy shall become effective after the effectiveness of the Company’s initial public
offering (the “IPO”) and shall remain in effect until it is revised or rescinded by further action of the Board. This Policy may be amended, modified or terminated by the Board at any time in its sole discretion. The terms
and conditions of this Policy shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors and between
any subsidiary of the Company and any of its non-employee directors. 
 1. Cash Compensation.

 (a) Annual Retainers. Each Non-Employee Director shall receive an annual retainer of
$55,000 for service on the Board. 
 (b) Additional Annual Retainers. In addition, a
Non-Employee Director shall receive the following annual retainers: 
 (i) Chairperson of the
Board. A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $50,000 for such service. 

(ii) Lead Director of the Board. A Non-Employee Director serving as Lead Director of the Board
shall receive an additional annual retainer of $30,000 for such service. 
 (iii) Audit Committee. A
Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $20,000 for such service. A Non-Employee Director
serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $10,000 for such service. 

(iv) Compensation Committee. A Non-Employee Director serving as Chairperson of the Compensation
Committee shall receive an additional annual retainer of $15,000 for such service. A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an
additional annual retainer of $7,500 for such service. 
 (v) Nominating and Corporate Governance Committee. A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service. A
Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service. 

 (vi) Compliance and Culture Committee. A
Non-Employee Director serving as Chairperson of the Compliance and Culture Committee shall receive an additional annual retainer of $10,000 for such service. A
Non-Employee Director serving as a member of the Compliance and Culture Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service. 

(c) Payment of Retainers. The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a
calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, such Non-Employee Director shall receive a prorated
portion of the retainer(s) otherwise payable to such Non-Employee Director for such calendar quarter pursuant to Sections 1(a) and 1(b), with such prorated portion determined by multiplying such otherwise
payable retainer(s) by a fraction, the numerator of which is the number of days during which the Non-Employee Director serves as a Non-Employee Director or in the
applicable positions described in Section 1(b) during the applicable calendar quarter and the denominator of which is the number of days in the applicable calendar quarter. 

2. Equity Compensation. Non-Employee Directors shall be granted the equity awards described
below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company’s 2020 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (such
plan, as may be amended from time to time, the “Equity Plan”) and shall be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms previously approved by the
Board. All applicable terms of the Equity Plan apply to this Policy as if fully set forth herein, and all equity grants hereunder are subject in all respects to the terms of the Equity Plan. 

(a) IPO Awards. Each Non-Employee Director who (i) serves on the Board as of the date the
IPO price of the shares of the Company’s common stock is established in connection with the Company’s IPO (the “Pricing Date”) and (ii) will continue to serve as a
Non-Employee Director immediately following the Pricing Date shall be automatically granted, on the Pricing Date, an award of restricted stock units that have an aggregate fair value on the date of grant of
$152,000 (as determined in accordance with FASB Accounting Codification Topic 718 (“ASC 718”) and subject to adjustment as provided in the Equity Plan in each case). The awards described in this
Section 2(a) shall be referred to herein as the “IPO Awards”). 
 (b) Annual Awards. Each Non-Employee Director who (i) serves on the Board as of the date of any annual meeting of the Company’s stockholders (an “Annual Meeting”) after the Pricing Date and (ii) will
continue to serve as a Non-Employee Director immediately following such Annual Meeting shall be automatically granted, on the date of such Annual Meeting, an award of restricted stock units that have an
aggregate fair value on the date of grant of $152,000 (as determined in accordance with ASC 718 and subject to adjustment as provided in the Equity Plan). The awards described in this Section 2(b) shall be referred to as the “Annual
Awards.” For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an Annual Meeting shall receive only an Annual Award in connection with such election, and
shall not receive any Initial Award on the date of such Annual Meeting as well. 

 (c) Initial Awards. Except as otherwise determined by the Board, each Non-Employee Director who is initially elected or appointed to the Board after the Pricing Date on any date other than the date of an Annual Meeting shall be automatically granted, on the date of such Non-Employee Director’s initial election or appointment (such Non-Employee Director’s “Start Date”), an award of restricted stock units that
have an aggregate fair value on such Non-Employee Director’s Start Date equal to the product of (i) $152,000 (as determined in accordance with ASC 718) and (ii) a fraction, the numerator of which is
(x) 365 minus (y) the number of days in the period beginning on the date of the Annual Meeting immediately preceding such Non-Employee Director’s Start Date (or, if no such Annual Meeting has
occurred, the effective date of the Company’s IPO) and ending on such Non-Employee Director’s Start Date and the denominator of which is 365 (with the number of shares of common stock underlying each
such award subject to adjustment as provided in the Equity Plan). The awards described in this Section 2(c) shall be referred to as “Initial Awards.” For the avoidance of doubt, no
Non-Employee Director shall be granted more than one Initial Award. 
 (d) Termination of
Employment of Employee Directors. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and
remain on the Board will not receive an Initial Award pursuant to Section 2(c) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or
subsidiary of the Company, Annual Awards as described in Section 2(b) above. 
 (e) Vesting of Awards Granted to Non-Employee Directors. Each IPO Award shall vest and become exercisable on the first anniversary of the date of grant, subject to the Non-Employee Director continuing in
service on the Board through the applicable vesting date. Each Annual Award shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the
first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date. Each Initial Award shall vest and become exercisable in
three equal installments, with the first installment vesting and becoming exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the first anniversary of
the date of grant (such earlier date, the “Installment Vesting Date”) and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively,
in each case subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date. No portion of an IPO Award, Annual Award or Initial Award that is unvested or
unexercisable at the time of a Non-Employee Director’s termination of service on the Board shall become vested and exercisable thereafter. All of a Non-Employee
Director’s IPO Awards, Annual Awards and Initial Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time. 

 3. Expenses 

The Company will reimburse each Non-Employee Director for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board meetings and meetings of any committee of the
Board; provided, that the Non-Employee Director timely submit to the Company appropriate documentation substantiating such expenses in accordance with the Company’s travel and expense policy
applicable to directors, as in effect from time to time. To the extent that any taxable reimbursements are provided to any Non-Employee Director, they will be provided in accordance with Section 409A of
the Internal Revenue Code of 1986, as amended, including, but not limited to, the following provisions: (i) the amount of any such expenses eligible for reimbursement during such individual’s taxable year may not affect the expenses
eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense must be made no later than the last day of such individual’s taxable year that immediately follows the taxable year in which the expense
was incurred; and (iii) the right to any reimbursement may not be subject to liquidation or exchange for another benefit. 
 * * * * *EX-10.52

 Exhibit 10.52 

 

					
	

	  	 Bioventus

4721 Emperor Blvd., Suite 100
 Durham, NC 27703

USA
	    	 1-919-474-6700
 1-800-396-4325
www.BioventusGlobal.com

 February 5, 2021 
 Kenneth
Reali 
  

	Re:	 Employment Agreement 

Dear Ken, 
 This Employment Letter Agreement (this
“Agreement”) is entered into by and between you, Bioventus Inc. (the “Corporation”) and Bioventus LLC (the “Partnership” and, together with the Corporation and any of the affiliates of the
Corporation or the Partnership as may employ you from time to time, “Bioventus”). This Agreement is an amendment and restatement of the certain Employment Offer letter dated as ofMarch 12, 2020 and amended on April 24,
2020 by and between you and the Partnership, pursuant to which you are employed as the Chief Executive Officer of the Partnership (the “Prior Agreement”) and supersedes the Prior Agreement in its entirety, effective as of the
date of the consummation of the initial public offering of the Corporation’s common stock (the “Effective Date”). 
  

	 	1.	 Employment and Duties 

Effective as of the Effective Date, you will be employed in the role of Chief Executive Officer of the Corporation and the Partnership and you shall
perform the duties of this role as are customary and as may be required by Bioventus from time to time. You will continue reporting to the Board and you will be based at the headquarters of Bioventus currently located in Durham, NC. 

You shall continue to have such duties and responsibilities, commensurate with your position, as may be reasonably assigned to you from time to time by the
Board of Directors of the Corporation (the “Board”)], or which are in accordance with the delegations of authority set out by the Board. 

During your employment with Bioventus, you will devote your full-time best efforts and business time and attention to the business of Bioventus. 

 

	 	2.	 At-Will Employment Relationship 

You may terminate your employment with Bioventus at any time and for any reason whatsoever simply by providing Bioventus with thirty (30) days’
advance written notice. Likewise, Bioventus may terminate your employment at any time, with or without Cause, and with or without advance notice, subject to the severance obligations set forth in Section 6. Your employment at-will status can only be modified in a written agreement approved by Bioventus and signed by you and a duly authorized member of Bioventus. 

 

	 	3.	 Base Salary and Employee Benefits 

Your base salary will be paid at the annual rate of $700,000 (the “Annual Base Salary”) less payroll deductions and
withholdings. You will be paid your Annual Base Salary on a bi-weekly basis, on Bioventus’ normal payroll schedule. You will be reimbursed for expenses that are normal and customary for your role and
follow applicable Bioventus policies. As an exempt salaried employee, you will be required to work Bioventus’ normal business hours, and such additional time as appropriate for your work assignments and position. You will not be eligible for
overtime premiums. 
 You will be eligible to participate in Bioventus’ equity incentive plans, and the health and welfare, group insurance, retirement
and other employee benefit plans, programs and arrangements (pursuant to the terms and conditions of the benefit plans and applicable policies) as are made generally available from time to time to executives of Bioventus. Additionally, on or about
the Effective Date, you will receive an equity award under the Bioventus 2021 Equity Incentive Plan in a form and amount to be determined by the Board in its sole discretion. 

 

 Kenneth Reali 

February 5, 2021 
 Page 2 

 

 You will continue to be eligible for twenty-five days of vacation per year. 

 

	 	4.	 Annual Performance Bonus and Merit Planning 

You will continue to be eligible to participate in the Bioventus Global Annual Incentive Plan or any sub-plan thereof
or any other bonus program as determined by Bioventus from time to time (the “Annual Incentive Plan”) at an annual target of one hundred percent (100%) of your Annual Base Salary (your “Annual Bonus”).
The Annual Incentive Plan may include components of your personal performance as well as Bioventus’ business objectives. The terms and conditions of your Annual Incentive Plan will be set forth in the Annual Incentive Plan documents. 

Your performance will be reviewed on a yearly basis by the Board. At that time, your salary will be reviewed along with your performance to determine any
adjustment to your Annual Base Salary. 
  

	 	5.	 Certain Definitions 

For purposes of this Agreement, the following definitions will apply: 
  

	 	a.	 Definition of Change in Control. “Change in Control” shall have the meaning provided in the
Bioventus 2021 Equity Incentive Plan as of the Effective Date; provided that such Change in Control also constitutes a “change in control event,” as defined in Treasury Regulation
Section 1.409A-3(i)(5). 

  

	 	b.	 Definition of Cause. “Cause” for Bioventus to terminate your
employment shall exist if any of the following occurs: (A) your being convicted (including a guilty plea or plea of nolo contendere) of any felony or any other crime involving fraud, violence or dishonesty; (B) your commission of or
participation in a fraud or act of dishonesty or misrepresentation against Bioventus; (C) your material violation of any written and fully executed contract or agreement between you and Bioventus, including without limitation, breach of your
Restrictive Covenant Agreement (as defined below); (D) your gross negligence or willful misconduct; (E) your continued and substantial failure to perform your duties to Bioventus set forth herein at a level commensurate with your
position; or (F) your violation of any material policies, practices, or procedures of Bioventus. 

  

	 	c.	 Definition of Good Reason. “Good Reason” for you to terminate your
employment shall mean the occurrence of any one of the following events without either (x) your express prior written consent or (y) full cure within 30 days after you give written notice to Bioventus: (i) material diminution in
duties or responsibilities; (ii) a material reduction in your salary, except for across-the-board salary reductions similarly affecting all senior executive
officers of Bioventus; (iii) the relocation of your principal office, or principal place of employment, to a location more than fifty (50) miles from the location of your principal office or principal place of business as of the Effective
Date; or (iv) a failure to pay you earned compensation; provided however, that no event shall constitute grounds for a Good Reason termination unless you provide written notice to Bioventus of the event or condition purported to constitute Good
Reason within 90 days of the initial existence of such event or condition and you terminate your employment within 60 days after such notice is provided. 

 Kenneth Reali 

February 5, 2021 
  Page
 3
 
  

	 	6.	 Severance Benefits 

 

	 	a.	 If, at any time, Bioventus terminates your employment without Cause (other than as a result of your
death or disability) or you terminate your employment for Good Reason, then, subject to Section 6(c) and Section 7, you shall receive the following severance benefits (the “Severance Benefits”): (i)
eighteen (18) months (of your Annual Base Salary in effect on the effective date of termination (the “Termination Date”), less applicable taxes and withholdings, payable in equal installments over the
eighteen (18) month period immediately following the Termination Date (the “Severance Period”) in accordance with Bioventus’ regular payroll practices in effect as of the Termination Date; (ii) one hundred
fifty percent (150%) of your target Annual Bonus, less applicable taxes and withholdings, payable in equal installments over the Severance Period in accordance with Bioventus’ regular payroll practices in effect as of the Termination Date;
(iii) if you timely elect continued coverage under federal COBRA laws or comparable state insurance laws (“COBRA”), then Bioventus shall pay the COBRA premiums necessary to continue your medical and dental
insurance coverage in effect for yourself and your eligible dependents during the Severance Period (provided that such COBRA reimbursement shall terminate on such earlier date as you are no longer eligible for COBRA coverage or you become eligible
for group health insurance benefits through a new employer). 

  

	 	b.	 If, during the two-year period immediately following a Change in
Control, Bioventus terminates your employment without Cause (other than as a result of your death or disability) or you terminate your employment for Good Reason, then, subject to Section 6(c) and Section 7, you shall receive the following
severance benefits (the “CIC Severance Benefits”): (i) twenty four (24) months of your Annual Base Salary in effect on the Termination Date, less applicable taxes and withholdings, payable in a lump sum payment on the first
payroll date on or following the 60th day after the Termination Date (the “CIC Severance Payment Date”); (ii) two hundred percent (200%) of your target Annual Bonus, less applicable taxes and withholdings, payable in a lump sum on
the CIC Severance Payment Date; (iii) a lump sum payment equal to twenty-four (24) months of COBRA premium payments (determined as of the Terminate Date) for your medical and dental insurance coverage in effect for yourself and your
eligible dependents as of the Termination Date, less applicable taxes and withholding, payable on the CIC Severance Payment Date; and (iv) full acceleration of all of your outstanding equity awards as of the Termination Date.

  

	 	c.	 Your receipt of the Severance Benefits or CIC Severance Benefits, as applicable, is conditional upon
(a) your continuing to comply with your obligations under your Restrictive Covenant Agreement; and (b) your executing and delivering an effective, general release of all known and unknown claims in favor of Bioventus, in Bioventus’
customary form (a “Release”) within 45 days following the Termination Date (and not revoking the Release). 

  

	 	d.	 The provisions of this Agreement shall supersede in their entirety any severance payment or benefit
obligations to you pursuant to the provisions in any severance plan, policy, program or other arrangement maintained by Bioventus. 

  

	 	7.	 Section 409A 

 

	 	a.	 General. The parties hereto acknowledge and agree that, to the extent applicable, this
Agreement shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder (collectively,
“Section 409A”). Notwithstanding any provision of this Agreement to the contrary, in the event that Bioventus determines that any amounts payable hereunder will be immediately taxable to you under
Section 409A, Bioventus reserves the right (without any obligation to do so or to indemnify you for failure to do so) to (i) adopt such amendments to this Agreement and appropriate policies and procedures, including amendments and policies
with retroactive effect, that Bioventus determines to be necessary or appropriate to preserve the intended tax treatment of the benefits provided by this Agreement, to preserve the economic benefits of this Agreement and to avoid less favorable
accounting or tax consequences for Bioventus and/or (ii) take such other actions as Bioventus determines to be necessary or appropriate to exempt the amounts payable hereunder from Section 409A or to comply with the requirements of
Section 409A and thereby avoid the application of penalty taxes thereunder. No provision of this Agreement shall be interpreted or construed to transfer any liability for failure to comply with the requirements of Section 409A from you or
any other individual to Bioventus or any of its Affiliates, employees or agents. 

 Kenneth Reali 

February 5, 2021 
  Page
 4
 
  

	 	b.	 Separation from Service under Section 409A. Notwithstanding any provision to
the contrary in this Agreement: (i) no Severance Benefits or CIC Severance Benefits shall be payable unless the termination of your employment constitutes a “separation from service” within the meaning of Section 1.409A-1(h) of the Department of Treasury Regulations; (ii) for purposes of Section 409A, your right to receive Severance Benefits in installment payments, if any, shall be treated as a right
to receive a series of separate and distinct payments; and (iii) to the extent that any reimbursement of expenses or in-kind benefits constitutes “deferred compensation” under Section 409A,
such reimbursement or benefit shall be provided no later than December 31 of the year following the year in which the expense was incurred. The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in
any subsequent year. The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year. Notwithstanding
any provision to the contrary in this Agreement, if you are deemed at the time of your separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of
any portion of the termination benefits to which you are entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of your termination benefits shall not be
provided to you prior to the earlier of (x) the expiration of the six-month period measured from the date of your “separation from service” with Bioventus (as such term is defined in the
Treasury Regulations issued under Section 409A of the Code) or (y) the date of your death; upon the earlier of such dates, all payments deferred pursuant to this sentence shall be paid in a lump sum to you, and any remaining payments due
under the Agreement shall be paid as otherwise provided herein. 

  

	 	c.	 Release. Notwithstanding anything to the contrary in this Agreement, to the extent that
any payments of “nonqualified deferred compensation” (within the meaning of Section 409A) due under this Agreement as a result of your termination of employment are subject to your execution and delivery of a Release, (i) the
Release shall be reasonable and drafted in good faith, (ii) Bioventus shall deliver the Release to you within ten (10) business days following the Termination Date, and Bioventus’ failure to deliver a Release prior to the expiration
of such ten (10) business day period shall constitute a waiver of any requirement to execute a Release, (iii) if you fail to execute the Release on or prior to the Release Expiration Date (as defined below) or timely revokes his acceptance
of the Release thereafter, you shall not be entitled to any payments or benefits otherwise conditioned on the Release, and (iv) in any case where the Termination Date and the Release Expiration Date fall in two separate taxable years, any
payments required to be made to you that are conditioned on the Release and are treated as nonqualified deferred compensation for purposes of Section 409A shall be made in the later taxable year. For purposes of this paragraph, “Release
Expiration Date” shall mean the date that is twenty-one (21) days following the date upon which Bioventus timely delivers the Release to you, or, in the event that your termination of employment
is “in connection with an exit incentive or other employment termination program” (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45) days following such delivery date. To
the extent that any payments of nonqualified deferred compensation (within the meaning of Section 409A) due under this Agreement as a result of your termination of employment are delayed pursuant to this paragraph, such amounts shall be paid in
a lump sum on the first payroll date following the date that you execute and do not revoke the Release (and the applicable revocation period has expired) or, in the case of any payments subject to clause (iv) of this paragraph, on the first
payroll period to occur in the subsequent taxable year, if later. 

 Kenneth Reali 

February 5, 2021 
  Page
 5
 
  

	 	8.	 Compliance with Restrictive Covenant Agreement and Bioventus Policies 

You acknowledge that you are, concurrently with the execution of this Agreement, entering into an agreement with Bioventus containing confidentiality, non-solicitation, non-competition, intellectual property assignment, and other protective covenants (the “Restrictive Covenant Agreement” attached hereto as
Exhibit A) and that you shall be bound by the terms and conditions of the Restrictive Covenant Agreement. In addition, you agree that you will abide by Bioventus’ Code of Conduct and Bioventus’ policies, as may be changed from time
to time at Bioventus’ sole discretion. 
  

	 	9.	 Outside Activities 

Throughout your employment with Bioventus, you may engage in civic and
not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or violate Bioventus’ Conflict of Interest
Policy. Specifically, under this provision you may, subject to review and approval by the Board in its sole discretion, serve on boards of directors of not-for-profit
entities and/or other boards. 
  

	 	10.	 Assignment 

This Agreement may be assigned by Bioventus to a person or entity which is an affiliate or a successor in interest to substantially all of the business
operations of Bioventus. Upon such assignment, the rights and obligations of Bioventus hereunder shall become the rights and obligations of such affiliate or successor person. You may not assign your rights or obligations to another entity or
person. 
  

	 	11.	 Indemnification 

You shall be entitled to indemnification to the maximum extent permitted by applicable law and Bioventus’ customary indemnification policies and
procedures applicable to Bioventus’ officers and directors. At all times during your employment, Bioventus shall maintain in effect a directors and officers liability insurance policy with you as a covered officer. Bioventus shall further
provide and pay for the defense of any action, arbitration or mediation (collectively, an “Action”) relative to the lawful performance of your duties or in connection with your employment at Bioventus and the existence of such
Action or defense shall not provide grounds for termination of your employment. 
  

	 	12.	 Whistleblower Protection and Trade Secrets 

Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits you from reporting possible violations of federal law or
regulation to any United States governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any
other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies). Furthermore, in accordance with 18 U.S.C. § 1833,
notwithstanding anything to the contrary in this Agreement: (a) you shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (i) for the disclosure of a trade
secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) for the disclosure of a trade secret that is made
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (b) if you file a lawsuit for retaliation by Bioventus for reporting a suspected violation of law, you may disclose the trade secret
to your attorney, and may use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order. 

 Kenneth Reali 

February 5, 2021 
  Page
 6
 
  

	 	13.	 Section 280G Parachute Payments 

Notwithstanding any other provision in this Agreement to the contrary, in the event that any payment or benefit received or to be received by you, pursuant to
this Agreement or otherwise, in connection with a Change in Control or otherwise would be considered an “excess parachute payment” within the meaning of Section 280G of the Code and the regulations thereunder, then such payments and
benefits will either be (i) delivered in full or (ii) reduced by the minimum amount necessary so that all of the remaining payments and benefits will not be subject to the excise tax imposed by Section 4999 of the Code, whichever of
the foregoing (i) or (ii) results in the greater net after-tax value of payment and benefits to you. All determinations regarding the application of this paragraph shall be made by an accounting firm or
consulting group with experience in performing calculations regarding the applicability of Sections 280G and 4999 of the Code selected by Bioventus, and all associated costs will be borne by Bioventus. 

 

	 	14.	 Compensation Recovery Policy 

You acknowledge and agree that, to the extent Bioventus adopts any clawback or similar policy pursuant to the Dodd-Frank Wall Street Reform and Consumer
Protection Act or otherwise, and any rules and regulations promulgated thereunder, you will take all action necessary or appropriate to comply with such a clawback policy (including, without limitation, entering into any further agreements,
amendments or policies necessary or appropriate to implement and/or enforce such policy). 
  

	 	15.	 Miscellaneous 

This Agreement, together with your Restrictive Covenant Agreement and all applicable equity award agreements, forms the complete and exclusive statement of
your employment agreement with Bioventus. Changes in your employment terms, other than those changes expressly reserved to Bioventus’ discretion in this Agreement, require a written modification approved by Bioventus. This Agreement will bind
the heirs, personal representatives, successors and assigns of both you and Bioventus, and inure to the benefit of both you and Bioventus, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or
unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties
insofar as possible under applicable law. This Agreement shall be construed and enforced in accordance with the laws of the State of North Carolina without regard to conflicts of law principles. The parties hereby irrevocably submit to the
jurisdiction of the state and federal courts of North Carolina located in or about Raleigh and waive any claim or defense of inconvenient or improper forum or lack of personal jurisdiction under any applicable law or decision. Any ambiguity in this
Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This
Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile or pdf signatures shall be equivalent to original signatures. 

[Signature pages follow] 

 Kenneth Reali 

February 5, 2021 
  Page
 7
 
  

 THE PARTIES ACKNOWLEDGE BY SIGNING BELOW THAT THEY HAVE READ AND UNDERSTAND THE ABOVE AND INTEND TO BE
BOUND THEREBY: 
  
  

									
	EMPLOYEE	  		  		  	BIOVENTUS INC.
					
		  	 /s/ Kenneth Reali
	  		  		  	 /s/ William Hawkins

	Name:	  	Kenneth Reali	  		  	Name:	  	William Hawkins
	Date:	  	2/9/2021	  		  	Its:	  	Chairman of the Board
					
		  		  		  		  	BIOVENTUS LLC
					
		  		  		  		  	 /s/ William Hawkins

		  		  		  	Name:	  	William Hawkins
		  		  		  	Its:	  	Chairman of the Board

 Kenneth Reali 

February 5, 2021 
  Page
 8
 
  

 EXHIBIT A 

RESTRICTIVE COVENANT AGREEMENT 

THIS RESTRICTIVE COVENANTS AGREEMENT (“Agreement”), dated as of the 3rd day of February, 2021, is made between Bioventus Inc.
(the “Corporation”), Bioventus LLC, a Delaware limited liability company (the “Partnership” and, together with the Corporation and any subsidiaries, parent companies or affiliates of the Corporation or the
Partnership, “Bioventus”), and Kenneth Reali (the “Executive”), a resident of the State of North Carolina. 

RECITALS 
 A. Bioventus
and the Executive have entered into that certain Employment Offer Letter dated the date hereof (the “Employment Agreement”). 

B. The Executive possesses extensive knowledge and experience regarding the business of Bioventus and shall benefit from the Employment
Agreement. 
 AGREEMENT 

NOW, THEREFORE, for good and valuable consideration, which includes Bioventus’ agreement to employ or continue to employ Executive under
the Employment Agreement and all payments and benefits available to Executive under the Employment Agreement, and in specific consideration for Bioventus’ agreement to provide the bonus payments set forth in the Employment Agreement, which
Executive acknowledges and agrees is valid and sufficient consideration for the following covenants in this Agreement, the parties hereto agree as follows: 

1. Confidential Information; Non-Disclosure. 

a. Non-Use and Non-Disclosure of Confidential
Information. Executive acknowledges that Executive currently holds and has access to proprietary and confidential information of Bioventus and its subsidiaries. Executive hereby covenants and agrees that neither Executive nor any of
Executive’s Affiliates (as hereinafter defined) will, at any time, divulge, furnish or make accessible to anyone or use in any way other than in the ordinary course of the business of Bioventus or its subsidiaries, any confidential, proprietary
or secret knowledge or information of Bioventus that Executive has acquired or shall acquire about Bioventus or its subsidiaries, whether developed by Executive or by others, including, without limitation, knowledge or information concerning
(i) any trade secrets, (ii) any confidential, proprietary or secret designs, programs, processes, formulae, plans, devices or material (whether or not patented or patentable) directly or indirectly useful in any aspect of the business of
Bioventus or its subsidiaries, (iii) any customer or supplier lists, (iv) any confidential, proprietary or secret development or research work, (v) any strategic or other business, marketing or sales plans, (vi) any financial
data or plans, or (vii) any other confidential or proprietary information or secret aspects of the business of Bioventus or its subsidiaries. Executive acknowledges that the above-described knowledge and information constitutes a unique and
valuable asset of Bioventus and its subsidiaries and represents a substantial investment of time and expense by Bioventus and its subsidiaries, and that any disclosure or other use of such knowledge or information other than for the sole benefit of
Bioventus or its subsidiaries would be wrongful and may cause irreparable harm to Bioventus and its subsidiaries (“Confidential Information”). Executive shall take reasonable steps to protect the confidentiality of all Confidential
Information. The foregoing obligations of confidentiality shall not apply to any knowledge or information that (i) is now or subsequently becomes generally publicly known, other than as a result of the breach of this Agreement, (ii) is
independently made available to Executive in good faith by a third party who has not violated a confidential relationship with Bioventus or any of its subsidiaries, or (iii) is required to be disclosed by law or legal process. Executive
understands and agrees that his obligations under this Agreement to maintain the confidentiality of Bioventus’ and its subsidiaries’ Confidential Information are in addition to any obligations of Executive under applicable statutory or
common law. For purposes of this Agreement, “Affiliate” shall mean any person or entity directly or indirectly controlled by the Executive. 

 Kenneth Reali 

February 5, 2021 
  Page
 9
 
  

 b. Company Property. As between Bioventus and Executive, all Confidential
Information will remain the exclusive property of Bioventus, including, but not limited to, all financial, commercial, operational, technical or business information or data received, obtained, or prepared by Executive in connection with
Executive’s employment or engagement and concerning Bioventus’ business, and all copies and abstracts thereof. Upon the termination of Executive’s employment or engagement with Bioventus for any reason, Executive will not retain,
take, remove, or copy any such property of Bioventus or any materials containing any Confidential Information whatsoever, and Executive will promptly return all such property and materials to Bioventus no later than Executive’s termination date
or earlier upon Bioventus’ request. 
 c. Exceptions; Notice of Legal Obligation to Disclose. Nothing in this Agreement
prohibits Executive from filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or otherwise cooperating with any governmental agency or from making other disclosures that are
protected under the whistleblower provisions of applicable law or regulation. Further, nothing herein prevents Executive from disclosing Confidential Information if and to the extent required pursuant to any valid subpoena, court order, or other
legal obligation; provided, however, Executive agrees to provide prompt written notice of any such subpoena, court order, or other legal obligation prior to disclosing any Confidential Information (unless such notice to Bioventus is prohibited by
applicable law), enclosing a copy of the subpoena, court order or other documents describing the legal obligation. In the event that Bioventus objects to the disclosure of Confidential Information, by way of a motion to quash or otherwise, Executive
agrees to not disclose any Confidential Information while any such objection is pending. 
 d. Defend Trade Secrets Act
Disclaimer. In compliance with the requirements of the Defend Trade Secrets Act, Executive understands that: (i) Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive will not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files
a lawsuit for retaliation by Bioventus for reporting a suspected violation of law, Executive may disclose trade secrets to Executive’s attorney and use the trade secret information in the court proceeding if Executive: (a) files any
document containing the trade secret under seal; and (b) does not disclose the trade secret, except pursuant to court order. 
 2.
Noncompetition and Nonsolicitation Covenants. 
 a. Agreement Not to Compete. Except for
Executive’s direct and indirect ownership of Bioventus, for a period starting as of the date hereof and ending on such date which is eighteen (18) months after Executive’s Termination Date (as defined in the Employment Agreement) or,
in the event of a Change of Control Termination (as defined in the Employment Agreement), such date which is twenty-four (24) months after Executive’s Termination Date (the “Restricted Period”), Executive shall not,
directly or indirectly, own, invest in, lend money to, acquire or hold any interest in, render services to, act as agent for, or otherwise engage in any business, in the United States or in any other location in which Bioventus is then doing
business, that is competitive with any business conducted by or under active consideration by Bioventus or its subsidiaries at any time during the period that the Executive is an employee, director or direct or indirect shareholder of Bioventus or
any of its subsidiaries (the “Protected Business”), it being acknowledged by Executive that the Protected Business includes the design, sale, marketing, or distribution of Bioventus’ and its subsidiaries’ products and
services. Ownership by Executive, as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation listed on a national securities exchange or publicly traded in the
over-the-counter market shall not constitute a breach of this Section 2(a). 

 Kenneth Reali 

February 5, 2021 
  Page
 10
 
  

 b. Agreement Not to Solicit Employees. Executive represents and warrants that
Executive has not, directly or indirectly, solicited for employment for any entity or person (other than for Bioventus) any current employee, consultant or other independent contractor of Bioventus. For the Restricted Period, Executive shall not,
directly or indirectly, hire, engage, solicit or attempt to solicit any person who is then an employee, consultant or independent contractor of Bioventus or any subsidiary of Bioventus. 

c. Agreement Not to Solicit Others. Executive represents and warrants that Executive has not, directly or indirectly, solicited
any customer, supplier, distributor or other business contact referred to below for the purposes set forth below (other than on behalf of Bioventus). For the Restricted Period, Executive shall not, directly or indirectly, in any manner or capacity,
including without limitation as a proprietor, principal, agent, partner, officer, director, stockholder, employee, member of any association, consultant or otherwise, (x) solicit or attempt to solicit any person or entity who was a customer of
Bioventus during the last twelve (12) months immediately preceding the date hereof or is a customer of Bioventus or any subsidiary of Bioventus during the Restricted Period, for the purposes of selling, marketing or distributing products or
services similar to the products or services designed, sold, marketed or distributed by Bioventus or any of its subsidiaries, and (y) solicit, request, advise or induce any supplier, distributor or other business contact of Bioventus or any
subsidiary to cancel, curtail or otherwise adversely change its relationship with Bioventus or its subsidiaries as it relates, directly or indirectly, to the Protected Business. 

d. Acknowledgment. Executive hereby acknowledges that the provisions of this Section 2 are reasonable
and necessary to protect the legitimate interests of Bioventus and that any violation of this Section 2 by Executive may cause substantial and irreparable harm to Bioventus to such an extent that monetary damages alone
would be an inadequate remedy therefor. 
 e. Assistance is Prohibited. Executive further agrees that Executive will not,
directly or indirectly, assist or encourage any other person in carrying out, directly or indirectly, any activity that would be prohibited by the above provisions of this Section 2 if such activity were carried out by
Executive, directly or indirectly, or induce any employee, or former employee of Bioventus to carry out, directly or indirectly, any such activity. 

f. Blue Pencil Doctrine. If the duration of, the scope of or any business activity covered by any provision of this
Section 2 is in excess of what is determined to be valid and enforceable under applicable law, such provision shall be construed to cover only that duration, scope or activity that is determined to be valid and enforceable.
Executive hereby acknowledges that this Section 2 shall be given the construction which renders its provisions valid and enforceable to the maximum extent, snot exceeding its express terms, possible under applicable law.

 3. Non-Disparagement. The Executive agrees not to disparage Bioventus, any of its
products, services, or practices, or any of its directors, officers, agents, representatives, partners, members, equity holders, or affiliates, either orally or in writing, at any time; provided, that the Executive may confer in confidence
with the Executive’s legal representatives and make truthful statements as required by law. 

 Kenneth Reali 

February 5, 2021 
  Page
 11
 
  

 4. Ownership of Inventions. 

a. Inventions. Subject to the limitations in Section 4(c) below, Bioventus will own all rights, title
and interest in and to (i) any invention, innovation, manufacturing process, trade secret, design, idea or improvement related, directly or indirectly, to Bioventus’ business, or any part thereof, and (ii) all copyrights, patents,
trademarks and trade names which Executive develops or creates, in whole or in part in the course of Executive’s employment or engagement with Bioventus (referred to as “Inventions”). Subject to the limitations in
Section 4(c) below, Executive will, and hereby does, assign to Bioventus, without requirement of further writing and without royalty or any other further consideration, my entire right, title and interest throughout the
world in and to all Inventions created, conceived, made, developed, and/or reduced to practice by Executive in the course of Executive’s employment or engagement with Bioventus and all intellectual property rights therein. Executive will
promptly tell Bioventus about and give Bioventus all information relating to any such Inventions. Executive acknowledges that all original works of authorship which are made by Executive (solely or jointly with others) within the scope of
Executive’s employment or engagement with Bioventus and which are eligible for copyright protection are “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101). Executive hereby
waives, and agrees to waive, any moral rights Executive may have in any copyrightable work Executive creates or has created on behalf of Bioventus. Executive will make and maintain adequate and current written records of all Inventions covered by
this Section 4(a). These records may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings, notebooks and any other format. These records shall be and remain the property of Bioventus at
all times and shall be made available to Bioventus at all times. 
 b. Cooperation. Executive will cooperate with Bioventus in
obtaining, maintaining and enforcing copyright, patent, trademark or other relevant protections for Inventions covered by Section 4(a), including executing such documents as Bioventus may request as necessary for such
protection. 
 c. Executive Inventions. Executive acknowledges that Bioventus will not own, and the assignment of Inventions
set forth in Section 4(a) above does not apply to, Inventions for which no equipment, supplies, facility, or trade secret information of Bioventus were used and which was developed entirely on Executive’s own time
(“Executive Inventions”), unless (i) the Invention relates (a) to Bioventus’ business or (b) to Bioventus’ actual or demonstrably anticipated research or development, or (ii) the Invention results from
any work performed by Executive for Bioventus. If Executive believes an Invention qualifies as an Executive Invention, Executive will provide Bioventus at the time of creation written evidence to substantiate such belief. If Executive incorporates
any Executive Inventions or portions thereof into any Inventions created or developed for Bioventus, Executive hereby grants Bioventus a perpetual, irrevocable, royalty-free, transferable license to copy, modify, prepare derivative works of, use,
perform, and display such Executive Invention solely in connection with the Invention. 
 5. Enforcement. Executive hereby
specifically acknowledges and agrees that the scope of the restrictions set forth in this Agreement is reasonable and necessary to ensure that Bioventus receives the value of the Employment Agreement and that violation of this Agreement will harm
Bioventus to such an extent that monetary damages alone would be an inadequate remedy. Therefore, in the event of any violation by Executive or any Affiliate: 

a. Bioventus (in addition to all other remedies Bioventus may have) shall be entitled to a temporary restraining order, injunction and other
equitable relief (without posting any bond or other security) restraining the violator from committing or continuing such violation, 
 b.
in the case of any violation of Section 2 hereof, as determined by a final judgment of court of competent jurisdiction, the duration of the non-compete period referred to therein
shall be extended beyond its then-scheduled termination date for a period equal to the duration of the violation, and 
 c. in the event
that Bioventus must enforce this Agreement pursuant to this Section 5, Bioventus shall be entitled to recover from Executive its reasonable costs associated therewith, including all reasonable attorneys’ and court
fees. 
 6. Use of Name. Neither Executive nor any Affiliate shall use the name “Bioventus,” any variants thereof,
or any confusingly similar name, in any business (other than Bioventus) in which any of them is associated as shareholder, investor, lender, partner, co-venturer, co-marketer, sole proprietor, director,
officer, employee, agent, consultant, independent contractor or in any other capacity. 

 Kenneth Reali 

February 5, 2021 
  Page
 12
 
  

 7. No Violation of Other Agreements. Executive hereby represents and agrees
that neither (a) Executive’s entering into this Agreement nor (b) Executive’s carrying out the provisions of this Agreement, will violate any other agreement (oral, written or other) to which Executive is a party or by which
Executive is bound. 
 8. At-Will Employment; No Contract of Employment. Nothing
herein shall be deemed to create a contract of employment for any term. Executive acknowledges and agrees that Executive’s employment with Bioventus is and shall remain at all times at will, unless otherwise specified by the Employment
Agreement. 
 9. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of Executive, Bioventus
and their respective heirs, personal representatives, successors and assigns (including without limitation any assignee of substantially all of the assets of Bioventus); provided, however, that this Agreement may not be assigned by Executive. 

10. Complete Agreement. This Agreement contains the complete agreement between the parties hereto with respect to the matters
covered herein, and supersedes all prior agreements and understandings between the parties hereto with respect to such matters. This Agreement may be amended, terminated or superseded only by an agreement in writing executed by both parties hereto.

 11. Partial Invalidity. If any covenant or other provision of this Agreement is deemed invalid, illegal or incapable of
being enforced by reason of any rule of law or of any public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect and no covenant or provision shall be deemed dependent upon any other
covenant or provision unless so expressed herein. 
 12. No Waiver. No term or condition of this Agreement shall be deemed to
have been waived, nor shall there be any estoppel to enforce any provision of this Agreement, except by a statement in writing signed by the party against whom enforcement of the waiver or estoppel is sought. Any written waiver shall not be deemed a
continuing waiver unless specifically stated, shall operate only as to the specific term or condition waived and shall not constitute a waiver of such term or condition for the future or as to any act other than that specifically waived. 

13. Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original but both of
which shall constitute but one instrument. 
 14. Headings. The headings contained in this Agreement are for reference
purposes only and shall not be deemed to be a part of this Agreement or to affect the meaning or interpretation of this Agreement. 
 15.
Notices. All notices, requests, demands and other communications provided for in this Agreement shall be in writing delivered personally or sent by registered or certified mail, postage prepaid, as follows: 

 

					
	If to Bioventus:	  	Bioventus, Inc.	  	
		  	4721 Emperor Blvd., Suite 100	  	
		  	Durham, NC 27703	  	
		  	Attn: Leigh Ann Stradford	  	
			
	with a copy to:	  	Latham & Watkins, LLP	  	
		  	885 Third Avenue	  	
		  	New York, NY 10022	  	
		  	Attn: Rifka Singer	  	
			
	If to Executive:	  	To the address in Bioventus’ records	  	
			
	with a copy to:	  	                                      
                  	  	
		  	                                      
                  	  	
		  	                                     
                   	  	

 Kenneth Reali 

February 5, 2021 
  Page
 13
 
  

 16. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of North Carolina, without giving effect to any choice or conflict of law provision or rule, whether of the State of North Carolina or any other jurisdiction, that would cause the application of laws of any
jurisdiction other than the State of North Carolina. 
 17. Action of Affiliates. Executive shall cause his Affiliates not to
take any action that is prohibited to be taken by such Affiliates under the terms of this Agreement. 
 **[Signature Pages Follow]** 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first above written. 
  

			
		 	BIOVENTUS INC.
		
	By:	 	 /s/ Leigh Ann Stradford

	Name:	 	Leigh Ann Stradford
	Its:	 	SVP & Chief Human Resources Officer

  

			
		 	BIOVENTUS LLC
		
	By:	 	 /s/ Leigh Ann Stradford

	Name:	 	Leigh Ann Stradford
	Its:	 	SVP & Chief Human Resources Officer

  

			
		 	EXECUTIVE
		
	           	 	 /s/ Kenneth Reali

		 	Kenneth Reali

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]